ICD-related Risk Model Predicts the Prognosis and Immunotherapy Response of Patients with Liver Cancer

Overview

Journal Front Pharmacol

Date 2023 Jun 26

PMID 37361216

Authors

Duntao Su

Zeyu Zhang

Fada Xia

Qiuju Liang

Yuanhong Liu

Wei Liu

Zhijie Xu

Affiliations

Soon will be listed here.

Abstract

Immunogenic cell death (ICD) is a novel cell death mechanism that activates and regulates the immune system against cancer. However, its prognostic value in liver cancer remains unclear. Here, several algorithms such as correlation analysis, Cox regression analysis, and Lasso regression analysis were carried out to evaluate the prognostic value of ICD-related genes in patients with liver cancer. Three ICD-related prognostic genes, the prion protein gene (PRNP), dynamin 1-like gene (DNM1L), and caspase-8 (CASP8), were identified and used to construct a risk signature. Patients with liver cancer were categorized into high- and low-risk groups using the ICD-related signature. Subsequently, a multivariate regression analysis revealed that the signature was an independent risk factor in liver cancer [hazard ratio (HR) = 6.839; 95% confidence interval (CI) = 1.625-78.785]. Patient survival was also predicted using the risk model, with area under the curve values of 0.75, 0.70, and 0.69 for 1-, 3-, and 5-year survival, respectively. Finally, a prognostic nomogram containing the clinical characteristics and risk scores of patients was constructed. The constructed ICD-related signature could serve as a prognostic and immunotherapeutic biomarker in liver cancer.

Citing Articles

Vesicle-mediated transport-related genes predict the prognosis and immune microenvironment in hepatocellular carcinoma.

Ye Z, Wang Y, Yuan R, Ding R, Hou Y, Qian L J Cancer. 2024; 15(12):3645-3662.

PMID: 38911369 PMC: 11190757. DOI: 10.7150/jca.94902.

References

Huang Q, Zhan L, Cao H, Li J, Lyu Y, Guo X . Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways. Autophagy. 2016; 12(6):999-1014. PMC: 4922447. DOI: 10.1080/15548627.2016.1166318. View

Scirocchi F, Napoletano C, Pace A, Rahimi Koshkaki H, Di Filippo A, Zizzari I . Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib. Front Oncol. 2021; 11:755433. PMC: 8564482. DOI: 10.3389/fonc.2021.755433. View

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

Zhao T, Guo B, Xiao C, Chen J, Lu C, Fang F . Aerobic exercise suppresses hepatocellular carcinoma by downregulating dynamin-related protein 1 through PI3K/AKT pathway. J Integr Med. 2021; 19(5):418-427. DOI: 10.1016/j.joim.2021.08.003. View

Ladoire S, Enot D, Andre F, Zitvogel L, Kroemer G . Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy. Oncoimmunology. 2016; 5(2):e1082706. PMC: 4801435. DOI: 10.1080/2162402X.2015.1082706. View

Ma M, Lin X, Liu H, Zhang R, Chen R . Suppression of DRP1‑mediated mitophagy increases the apoptosis of hepatocellular carcinoma cells in the setting of chemotherapy. Oncol Rep. 2020; 43(3):1010-1018. DOI: 10.3892/or.2020.7476. View

Deng H, Yang W, Zhou Z, Tian R, Lin L, Ma Y . Targeted scavenging of extracellular ROS relieves suppressive immunogenic cell death. Nat Commun. 2020; 11(1):4951. PMC: 7532538. DOI: 10.1038/s41467-020-18745-6. View

Zhang Y, Chen Y . Stratification From Heterogeneity of the Cell-Death Signal Enables Prognosis Prediction and Immune Microenvironment Characterization in Esophageal Squamous Cell Carcinoma. Front Cell Dev Biol. 2022; 10:855404. PMC: 9040162. DOI: 10.3389/fcell.2022.855404. View

Zheng S, Xie X, Guo X, Wu Y, Chen G, Chen X . Identification of a Pyroptosis-Related Gene Signature for Predicting Overall Survival and Response to Immunotherapy in Hepatocellular Carcinoma. Front Genet. 2021; 12:789296. PMC: 8678488. DOI: 10.3389/fgene.2021.789296. View

10.

Li B, Severson E, Pignon J, Zhao H, Li T, Novak J . Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016; 17(1):174. PMC: 4993001. DOI: 10.1186/s13059-016-1028-7. View

11.

Zheng C, Zheng L, Yoo J, Guo H, Zhang Y, Guo X . Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. Cell. 2017; 169(7):1342-1356.e16. DOI: 10.1016/j.cell.2017.05.035. View

12.

Boege Y, Malehmir M, Healy M, Bettermann K, Lorentzen A, Vucur M . A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development. Cancer Cell. 2017; 32(3):342-359.e10. PMC: 5598544. DOI: 10.1016/j.ccell.2017.08.010. View

13.

Tibshirani R . The lasso method for variable selection in the Cox model. Stat Med. 1997; 16(4):385-95. DOI: 10.1002/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3. View

14.

Hao X, Sun G, Zhang Y, Kong X, Rong D, Song J . Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges. Front Cell Dev Biol. 2021; 9:775462. PMC: 8633569. DOI: 10.3389/fcell.2021.775462. View

15.

Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Buque Martinez A . Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020; 8(1). PMC: 7064135. DOI: 10.1136/jitc-2019-000337. View

16.

Markham A . Lurbinectedin: First Approval. Drugs. 2020; 80(13):1345-1353. DOI: 10.1007/s40265-020-01374-0. View

17.

Gao X, Huang H, Pan C, Mei Z, Yin S, Zhou L . Disulfiram/Copper Induces Immunogenic Cell Death and Enhances CD47 Blockade in Hepatocellular Carcinoma. Cancers (Basel). 2022; 14(19). PMC: 9564202. DOI: 10.3390/cancers14194715. View

18.

Wu W, Xue X, Chen Y, Zheng N, Wang J . Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies. Pharmacol Res. 2022; 184:106456. DOI: 10.1016/j.phrs.2022.106456. View

19.

Oura K, Morishita A, Tani J, Masaki T . Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. Int J Mol Sci. 2021; 22(11). PMC: 8198390. DOI: 10.3390/ijms22115801. View

20.

Li Z, Yang G, Han L, Wang R, Gong C, Yuan Y . Sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma. J Nanobiotechnology. 2021; 19(1):360. PMC: 8576878. DOI: 10.1186/s12951-021-01095-w. View